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Somatic mutations have been implicated as critical early events in carcinogenesis. Point mutations,
deletions, andtranslocation events havebeen shownto activate oncogenes orinactivate suppressoroncogenes.
Inhumanpopulation monitoring, quantitative analysisofmutation eventsthataffectgenefunction is limited
to those genes whose cellular phenotypes can be identified by selection procedures and to those tissues (like
blood) thatare accessible foranalysis. In an efforttodetermine the frequencyandtypesofmutations thatcan
be detected at the hypoxanthine guanine phosphoribosyltransferase (hprt) gene, we have used the T-cell
cloningassayandhavedevelopedastrategytopropagatemutantsandscreenforpointmutationsandbreakage
events.Earlyintheclonalexpansionofmutants,1-2 x 104cellsarepreparedasacrudecelllysate,andasample
is analyzed using the multiplex polymerase chain reaction (PCR). Those mutants that yield altered DNA
fragments are then expanded for Southern blot hybridization, PCR, flanking probe isolation, and DNA
sequencing. To date we have found presumed point mutations, intragenic deletions, and deletions that extend
outsideofthehprtgene.Byanalyzingmutations inselectable, nonessential genemarkers,itshouldbepossible
tounderstand mechanisms ofboth spontaneous and inducedgenetic damage. An association ofthese specific
genetic events with human diseases and the evaluation ofthe ability of environmental chemicals to induce
these specific types of mutations will lead to a rational basis for evaluating risks from various chemical
exposures.
Introduction
When evaluating the risks to human populations from
particular environmental exposures, it is important to
approach the analysis with an integrated investigation.
The mostinformative approach is to combine environmen-
tal exposure monitoring with biological techniques that
can provide insight into actual internal human exposure,
dose to a relevant target tissue, markers of biological
effect and, ultimately, measures of human disease.
Although the most useful data on which to conduct a risk
assessment may come fromepidemiological studies identi-
fying cancer or other human disease, one would like to
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identify potential adverse exposures before significant
numbers ofindividuals areaffected.Thus,itseemsreason-
able to develop and characterize markers of biological
effect for identifying adverse exposure scenarios.
Because ofthe association ofmutational eventswith the
etiology of cancer, a number of genetic damage assays
havebeenusedtodetectthepotentialofvariouschemicals
and physical agents to cause genotoxic effects. The range
and types ofmutational events associated with cancer and
other diseases include point mutations, deletions, trans-
locations, mitotic recombination, gene conversion, gene
amplification, and aneuploidy. It seems obvious that an
analysis ofvariousgenetic assays shouldinclude anunder-
standing ofthe spectrum of genetic damage detected by
that assay.
In human population monitoring, the quantitative anal-
ysis ofmutation events that affect gene function is limited
to those geneswhose cellularphenotypes canbeidentified
by selection procedures and to those tissues (like blood)
that are accessible for analysis. To determine the fre-
quency and types ofmutations that can be detected atthe
hprt gene, we have used the T-cell cloning assay (1,2) and
developed a strategy to propagate mutants and screen for
point mutations and breakage events.MOORE ETAL.
Earlier, invitro studies using quantitative comparisons
between autosomal markers (like thymidine kinase [tk])
and X-linked markers (like hprt) have demonstrated that
autosomal markers candetectthe clastogenicityofchemi-
cals, whereas X-linked markers severely underestimate
theclastogenicity oftestchemicals (3). Onepossiblemech-
anism for these differences is the potential nonviability of
hprt mutants containing multilocus deletions. Thus, to
understand the ability ofthe hprt locus oflymphocytes to
detectlarge-scale deletions, wehaveinitiallyconcentrated
on the analysis ofhprt deletion mutants.
Materials and Methods
Healthy volunteers were enrolled by advertisements in
the local media. Informed consent was obtained using
procedures approved by Institutional Review Boards for
theprotection ofhuman subjects. Specimens ofanticoagu-
lated peripheralbloodwere obtained andprocessed onthe
same day. Mononuclear cells were isolated by density
gradient centrifugation.
Cryopreservation ofLymphocytes
Lymphocytes were counted using a hemocytometer,
centrifuged, and resuspended in 20% defined/supple-
mentedbovinecalfserum(CBS; Hyclone, Logan,UT;heat
inactivated for 30 min at 57°C), 70% RPMI 1640 medium
(RPMI; Gibco, Grand Island, NY), and 10% dimethyl
sulfoxide. Twentymillion lymphocytes were aliquoted into
cryogenic vials. All vials were placed in a cryomed cell
freezer (Cryomed; Cryomed, New Baltimore, MI) at an
internal temperature of4°C. The cryomed cooled the cells
at1°C/min until the temperature reached -45°C and then
at10°C/min untilitreached -90°C. Cellswerethen stored
in liquid nitrogen units.
Lymphocyte Culture
Frozen lymphocytes were rapidly thawed and placed in
a mixture of 50% CBS and 50% RPMI. Cells were cen-
trifuged at 250g, resuspended in 10 mL ofRPMI, washed
twice with RPMI, resuspended in 5 mL of RPMI, and
viablecell numberwas determined usingahemocytometer
to determine recovery and viability using eosin viability
stain (Sigma, St. Louis, MO).
Cells for in vivo experiments were primed for 21-25 hr
in 70% RPMI, 20% HL-1 medium (Ventrex, Portland,
MN), 10% CBS, and 1 p.g/mL phytohemagglutinin (PHA;
Burroughs Wellcome, Research Triangle Park, NC).
Feeder Cells
Two different feeder cell lines were used for these
experiments. A spontaneous hprt-deficient subclone (pro-
vided by the University ofVermont) of the TK6 cell line
(derived from the human lymphoblastoid cell line WIL-2)
andtheX3C cellline (4) (derived as anX-ray-induced hprt
deletion mutant from a TK6 cell line, produced by Jean
WhaleyandprovidedbyHoward Liber, HarvardSchool of
Public Health). For use as feeders, cells were irradiated
with 8000 rad from a cesium source.
In Vivo Assay
Cells were plated in 96-well, round-bottom, microtiter
plates (Nunc, Naperville, IL) atcell densities of1,2, 5, and
10 cells/well to determine cloning efficiency and at 1-2 x
104cells/wellforhprtmutantselection.Cellswereplatedin
200 ,L ofmedium containing 20% growth factor supple-
ment, 20% HL1, 5% CBS, 55% RPMI, and 0.25 pLg/mL
PHA with 1 x 104 irradiated feeder cells/well. Growth
factor supplement (kindly provided by the University of
Vermont; Burlington, VT) is the cell-free supernatant
medium used in the lymphokine activated killer-cell ther-
apy. ThemethodforitspreparationisreportedbyBranda
et al. (5). Selection plates were supplemented with 10 AM
6-thioguanine (6-TG, Sigma).
In Vitro Assay
For in vitro treatments, cryopreserved lymphocytes
were thawed, washedwith fresh medium, and counted, as
above. Cells were then placed in tissue culture flasks and
gassed with 5% CO2 for overnight culture in a 37°C
incubator. When cells in the Go phase ofcell growth were
desired for chemical treatment, cells were cultured in
RPMI with 10% CBS. For chemical treatments using
proliferating cells, 1 ,ug/mL of PHA was added to stimu-
latethe cellsinto division. The cellswereincubatedfor21-
25 hr, centrifuged, resuspended in RPMI, and counted
with ahemocytometer. Cellswereprepared atadensityof
2 x 106 cells/mL in RPMI, and 5 mL of the cell culture
were added to 50 mL centrifuge tubes for treatment. The
test agent was added, cultures were gassed with 5% CO2
in air, and placed horizontallyin a 37°C incubatorfor 3 hr.
After treatment, cells were centrifuged at 250g and
washed three times with 10 mL of RPMI. After the final
wash, cells were resuspended in 5 mL RPMI and placed
into a 25-cm2 tissue culture flask. The tube was rinsed
with 5 mL of 40/10 medium (50% RPMI, 40% HL1, 10%
CBS), and the rinse was added to the tissue culture flask.
Cellsweregassedwith 5% CO2 in airandplaced in a37°C
CO2 incubatorfor2 days.
Two different techniques were used for the mutant
expression-mutant selection phases of the experiment.
Thefirsttechnique [standard (6)],modeledafterstandard
in vitro mutagenesis procedures, involved an expression
period duringwhich time the cell culture was maintained
in suspension culture. After the expression period, the
cells wereplated in 96-wellplateswith the selective agent.
The second technique (in situ), developed byO'Neill et al.
(7), involved plating cells into the 96-well plates on day 2
after treatment, allowing the cells to grow and the newly
induced mutants tobe expressed inthe 96-wellplates. The
selection agent was then added to the 96-well tray after
the5-dayexpressionperiod. Beforeconductingtheinsitu
protocol, the standard method was used to establish the
appropriate concentration range for the chemical treat-
ment.
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Scoring
Viable clones were scored using an inverted phase con-
trast microscope. Selection plates were scored 10-12 days
aftercloningandwere scored asecond time 5-7dayslater.
Survival and cloning efficiency plates were scored 14-15
days after cloning. On those occasions when nonmutant
clones were to be isolated for additional culture, these
plateswerefirstscored at10-12days, cloneswereisolated,
and final scoring was completed at 14-15 days after clon-
ing. Survival andcloningefficiencywith andwithoutselec-
tion were calculated using the Poisson distribution (po =
e-X, where po is the fraction of wells without colony
growth). Survival and cloning efficiencywith and without
selection = -lnPo x, where x is the average number of
cells plated per well. The mutant frequency is the ratio of
thecloningefficiencies inthepresence andabsenceof6TG
selection.
Mutant Isolation
The hprt mutants were isolated from selected experi-
ments. These cellswere cultured forcryopreservation and
molecular analysis. About one-half of the total volume of
media, 0.10 mL, was removed and discarded from the top
of each well containing a clone selected for isolation. The
clone was then carefully resuspended using a 1-mL pipet
andtransferred to asinglewellinanother96-wellmicroti-
terplate.Thewellwasfilledwithfreshgrowthmedia(20%
growth factor supplement, 20% HL1, 5% CBS, and 55%
RPMI with 0.25 [tg/mL PHA) containing 10 ,uM 6TG and
0.25 x 106irradiated feedercells/mL. Subsequent refeed-
ing and subculture were performed using the same
medium (without 6TG) and feeder cells. When sufficient
cells were present in the well, cells were resuspended in
medium, and the culture was divided among 2 (or more)
PCR
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individualwells ofthe 96-welltray.Atthetwo-well/mutant
stage, one well was used for multiplex PCR analysis.
Using the strategy outlined in Figure 1, the multiplex
PCR analysis was used to determine which mutants con-
tained total orpartial hprt gene deletions. Those mutants
were cultured to the extent oftheirviability and prepared
for cryopreservation and further molecular analyses.
Mutants that did not appear to resultfrom deletions were
not cultured further.
Cryopreservation ofMutants
One-half ofthe media was carefully removed (and dis-
carded) from the top ofeach mutant to be cryopreserved.
Cells were resuspended and counted using a hemocyto-
meter. Ifthe cell density was less than 2 x 106 cells/mL,
the cells were centrifuged for 10 min at 250g and resu-
spended in the supernatant at2 x 106 cells/mL. Atotal of
0.9mL ofcellswas added to acryogenicvial,mixedgently
with 0.9 mL of freezing media (84% CBS, 16% dimethyl
sulfoxide), and the vial was placed in a freezing collar
(Taylor-Wharton) for cryopreservation. The freezing col-
larwas setinposition E to allowthecellstocool at1°C min
to a temperature of -80°C and then placed in liquid
nitrogen.
In some cases, mutants did not grow to a concentration
that could be frozen in this manner. In those cases, cells
were counted, centrifuged for 10 min at 250g, and resus-
pended in 1.8 mL of 90% CBS, 10% dimethyl sulfoxide
containing a concentration of irradiated feeder cells
requiredtobringtheoverallcelldensity(lymphocytesand
feeder cells) to 3 x 106 cells/mL.
Multiplex PCR Analysis
Crudecellular extractswerepreparedbyamodification
ofthe method described by Higuchi (8). Briefly, 1-2 x 104
DNA Sequence
Analysis
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FIGURE 1. Schematic ofstrategy formolecular analysis ofhprt deletion mutations. Rapid PCR-based screening ofsmallsamples o;crude cell extracts
are used to quickly identify hprt deletion mutants as described in the text.
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cells were pelleted, washed in phosphate-buffered saline,
and resuspended in 50 FLL oflysis buffer consisting of 67
mM Tris-HCl pH 8.8,6.7mM MgCl2, 16.6 mM (NH4)2SO4,
5 mM 2-mercaptoethanol, 6.8 FLM EDTA, 0.45% Nonidet
P40, 0.45% Tween 20, and 100 VLg/mL proteinase K and
incubated for at least 1 hr at 56°C. The proteinase K was
then inactivated at 96°C for 10 min. The sample could be
stored at -80°C for at least 6 months before use. Five to
ten microliters, representing DNA from 1-4 x 103 cells,
were used in a 50-1LL multiplex hprt PCR reaction,
describedbyGibbs etal. (9).After33cycles, one-halfofthe
reaction was analyzed by agarose gel (1.4%) elec-
trophoresis for the presence ofindividual hprt exons and
changes in exon fragment size. After the initial screening,
larger amounts ofcrude extract at 2 x 106 cells/mL were
prepared for further analyses. Direct DNA sequencing of
PCR products was performed using primers and condi-
tions described previously (10,11).
Strategy for Breakpoint Analysis
Figure 1 shows our strategy foridentifying and analyz-
ing hprt deletion mutations. Crude cell extracts were first
analyzedbymultiplexhprtPCR asdescribed above.Those
mutants that showed awild-type pattern were not studied
further. Those that showed a weak signal, or no signal,
were candidates for containing total hprt gene deletions.
The same result, however, would be obtained if the PCR
reaction failed because of, for example, inhibitors from the
extracts or inadequate DNA. These extracts were, there-
fore, examined in a duplex PCR reaction in which an
unlinked gene segment (K-ras on chromosome 12) was
coamplified with hprt exon 6 (12). If awild-type pattern or
no K-ras signal was seenafter agarosegelelectrophoresis,
the mutant was not studied further. IfK-ras was present,
but the hprt exon 6 was absent, the mutation was a total
hprt gene deletion. Flanking primer pairs located
approximately 300 kb 3' and 350 kb 5' of the hprt gene
were then used in a duplex PCR assay with the K-ras
primers to determine how far the deletions extend beyond
hprt (12).
Ifthe original multiplex hprt PCR showed an alteration
in an exon fragment size, that exon wasindividually ampli-
fied and sequenced (11) to determine the deletion size and
the characteristics of the deletion junction. Hypotheses
concerning mechanisms were then formed for testing.
Finally, when the multiplex hprt PCR revealed missing
exon fragment(s), additional PCR reactions with intronic
primerpairs and Southernblothybridization were used to
localizethebreakpoints. Thebreakpointjunction wasthen
amplified by PCR for DNA sequence analysis.
Results and Discussion
The mutant frequency data for 19 separate determina-
tions is shown in Table 1. The mean mutant frequency for
all samples was 9.5 x 10-6,with a range of2.1-27 x 10-6.
In addition to the mutantfrequency, the age, sex, smoking
status, nonselective cloning efficiency, number of cells
plated for mutant selection, and the total number of
mutants are presented. Although our database is small, it
does appearthat, as has been shown by other laboratories
(13,14), there is an age-dependent increase in the mean
mutant frequency (Fig. 2). There does not appear to be an
increased hprt mutantfrequency among smokers. To date,
we have analyzed 165mutants from5individualsusingthe
multiplexPCR technique. Ofthese, 135 showed no change,
18showedpartialdeletionsand12 showedtotaldeletionsof
the hprt gene.
Examples ofmultiplex hprt PCR patterns are shown in
Figure 3. GM131 is an apparently normal lymphoblastoid
celllinewith anintacthprt gene andexhibits thewild-type
Table 1. Analysis ofhprt mutant frequency.
Cloning Mutant No. of cells
Donor Age Smoking efficiency, frequency, plated, Total no.
code (years) Sex statusa % x 10-6 x 106 ofmutantsb
A 28 M NS 29 8 10 23
B 28 M NS 29 2 10 6
C 31 M LS 44 5 20 41
D 31 M LS 8 10 20 15
E 26 M NS 18 3 9 4
F 21 M LS 22 8 16 27
G 24 F H 43 6 10 24
H 28 F LS 40 5 13 28
I 21 M LS 20 15 13 39
J 22 M LS 41 4 10 16
K 24 F H 53 4 12 26
L 28 F LS 44 9 12 42
M 21 M LS 51 6 12 36
N 26 M NS 27 12 58 167
0 70 F NS 33 16 4 22
P 67 M NS 46 10 5 23
Q 70 M NS 54 27 8.5 95
R 65 M NS 51 13 11.5 75
S 70 F NS 12 18 1.7 4
aSmoking status: NS, nonsmoker; LS, light smoker (1-15 cigarettes/day); h, heavy smoker (>15 cigarettes/day).
bTotal number of hprt mutants scored from the sample analyzed.
222QUALIFICATION AND MOLECULAR ANALYSIS OF hprt MUTANTS
30 exonsappearnormal.Wehavefoundthatexon4istheexon
A most frequently involved in small deletions. Mutant 73
shows loss of exons 2 and 3. We haverecently shown that
25- illegitimateactivityofV(D)Jrecombinase causes deletion
of hprt exons 2 and 3 (10). This mutant is, therefore, a
20 candidate for this type ofmutation.
A In an attempt to obtain more mutants with total hprt
A deletions, we performed several in vitro treatments with
15 bleomycin. After several unsuccessful attempts using the
A A standard method to grow mutants to sufficient numbers
'A for molecular analysis, we used the in situ method devel-
10 n A oped by O'Neill (7). Perhaps because the individual
mutants get a "head start" ofseveral cell divisions in the
wells during the expression phase before the addition of ..a
M the selective agent, we were more successful in culturing A mutants using this technique. Although the bleomycin-
0 1 0 0 8 induced mutant frequency was low in these experiments o 10 20 30 40 50 60 70 80 andthe number ofmutants available for studylikewiselow,
Age we were successful in finding 4-total deletion and 1
smokers non-smokers partial-hprt-deletion mutants out of 17 mutants studied
* A (Table 2). Of these mutants, 2 (one partial and one total
hprt gene deletion) came from an untreated culture.
The effect of age and smoking on the quantitated mutant BecausetheTK6feeder-celllinecontains anearlyintact
hprt gene, this DNA can serve as a substrate in the PCR
reactions and give rise to faint signals. (This can alsobe a
problem in Southern blot analyses). These signals can
make interpretation of the PCR gels difficult and may
require additional experiments to resolve. To avoid this
problem, we sought afeeder-cell line thatwas missingthe
E N - (N m ln hprt gene and alarge amount offlanking DNA. X3C (4)
wasfoundbymultiplexhprtPCR andK-ras/exon 6duplex
PCRtobemissingtheentirehprtgene.Bycoamplifyinga
(on* small region, about 350 kb 5' of the hprt gene with the
unlinked K-ras gene segment, the deletion was found to
include at least 350 kb upstream of the gene. Similarly,
duplex PCRwith K-ras and asegmentapproximately 300
kb3' ofhprtshowedthedeletionextendedatleastthatfar
downstreamofhprt.Thus,celllineX3Ccontainsadeletion
ofat least 700 kb around the hprt gene. This cell line has
proven comparable to TK6 in supporting the growth of
5 ~ T-lymphocytes in the hprt T-cell cloning assay (data not
shown) and has greatly simplified molecular analysis.
2 -
6-
4-
FIGURE 3. Multiplex hprt PCR analysis of HPRT-deficient human
T-lymphocyte clones. PCR products are displayed on a 1.4% agarose gel.
Mutants 62, 67, 72, 73, and 75 are from individual Q (Table 1). GM131 is a
lymphoblastoid linewith anormalhprt gene. DNAfromthislinedisplays
the wild-type pattern.
pattern, as do mutants 72 and 75. Mutant 62 does notgive
a signal and was subsequently found to be due to a total
hprt gene deletionbythe K-ras + hprt exon6duplexPCR
assay. Mutant 67 shows a deletion of exon 4, and other
Conclusions
Significant progresshasbeenmadeinunderstandingin
vitro gene mutation assays. Quantitative comparisons
between autosomal markers and X-linked markers have
demonstrated that autosomal markers, like the tk gene,
can detect the clastogenicity of chemicals, whereas
X-linked markers, like hprt, severely underestimate the
clastogenicity of test chemicals (3). There have been two
hypotheses to explain these differences: First, mutants
with deletions extending outside ofthe hprt locus are not
viable, but deletions extending outside ofthe tk locus are
viable. Second, a substantial number oftk mutants result
from mitotic recombination, a mechanism not available to
hemizygousloci. Ourcurrentstudies andthosebyNicklas
et al. (15) show that large deletions around hprt are
D
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X
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c-
(U)
-4-)
FIGURE 2.
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Table 2. Mutant frequency and molecular analysis ofhprt mutants from the in vitro treatment
oflymphocytes with bleomycin using the in situ technique.
Unselected Mutant
Bleomycin, Partial No. of cloning frequency,
,g/mL No changea deletion Total deletion mutantsb efficiency x 10-6
0 6 0 0 6 20 8
100 1 0 2 3 9 71
0 2 1 1 4 19 7
100 3 0 1 4 10 72
aNumber ofmutants showing no change ofband position using themultiplex hprt PCR anaylsis.
bTotal number ofmutants analyzed.
tolerated. This suggeststhatthedifferenceisnotduetoan
inability ofthe hprt locus to sustain large deletions. Fur-
thermore, our earlier investigations of tk mechanisms of
mutagenesis (16) suggest that a significant number of tk
mutants result from homologous mitotic recombination.
Inthepresentstudies,wehavedemonstrated ourability
to produce mutant frequency data similar to that pub-
lished by other laboratories. We have also begun to evalu-
atetherange andtypes ofgenetic damage detectedbythe
human T-lymphocyte hprt assay. Based on our data and
that of other laboratories, we know that the spectrum of
genetic damage detected includes point mutations (17,18)
and deletions ranging from a few base pairs, one or more
exons, the entire hprt gene and extensive numbers ofbase
pairsoutsideofthehprtgene.Wearecurrentlyworkingto
define the size ofthe maximum-tolerated deletion around
the hprt gene aswell as to determine themechanism(s) of
deletion formation.
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